<?xml version="1.0" encoding="UTF-8"?>
<p>Scale-up of PrEP access commenced in Australia in 2016 [
 <xref rid="pone.0204138.ref019" ref-type="bibr">19</xref>] through a series of clinical studies designed to provide interim PrEP access, while the public funding of for PrEP through the Australian Pharmaceutical Benefits Scheme (PBS) is being considered by the Pharmaceutical Benefits Advisory Committee [
 <xref rid="pone.0204138.ref020" ref-type="bibr">20</xref>]. Without the PBS subsidy, consumers have to pay the full cost of medicines.
</p>
